Anika Therapeutics, Inc. (ANIK) — Stock Score Summary

Anika Therapeutics, Inc. (ANIK) has a MoatMap StockRank of 94/100 based on Quality (52/100), Value (52/100), and Momentum (79/100) factor scores. The current signal is STRONG BUY. Anika Therapeutics is a micro-cap joint preservation company. It lacks the scale, pricing power, and commercial distribution network to compete effectively against major orthopedic players, making it a highly speculative investment.

Anika Therapeutics, Inc. is a global joint preservation company focused on developing and commercializing therapeutic products for pain management, tissue regeneration, and joint repair. Its proprietary hyaluronic acid technology and portfolio of FDA-approved products provide a strong foundation in orthopedic and aesthetic markets. Anika is a niche healthcare company specializing in biomaterial-based solutions for musculoskeletal conditions.

Key Financial Metrics

Price$14.57
Market Cap$198M
P/E (Forward)32.15
Price/Book1.48
Return on Equity-7.8%
Return on Invested Capital-6.6%
Debt/Equity19.22
Gross Margin58.6%
Operating Margin-18.5%
Revenue Growth13.2%
Free Cash Flow$6M

Anika Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Anika Therapeutics, Inc.’s (ANIK) StockRank?
MoatMap’s StockRank for Anika Therapeutics, Inc. (ANIK) is 94/100, with a Strong Buy signal. It is a composite of Quality (52), Value (52), and Momentum (79) factor ranks across MoatMap’s 19,000+ stock universe.
Does Anika Therapeutics, Inc. have an economic moat?
Anika Therapeutics, Inc. (ANIK) has a Quality factor score of 52/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Anika Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Anika Therapeutics, Inc. (ANIK) is Strong Buy, based on a StockRank of 94/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Anika Therapeutics, Inc. in?
Anika Therapeutics, Inc. (ANIK) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksANIK deep dive reportAI ChampionsHow we score stocksSense-check another stock